安旭生物9月25日获融资买入453.65万元，融资余额9361.94万元

Core Viewpoint - Anxu Bio experienced a slight increase in stock price and notable trading activity on September 25, 2023, with a focus on financing and stockholder data [1][2]. Group 1: Stock Performance and Trading Activity - On September 25, Anxu Bio's stock rose by 0.16%, with a trading volume of 17.95 million yuan [1]. - The financing buy-in amount for Anxu Bio on the same day was 4.54 million yuan, while the financing repayment was 2.36 million yuan, resulting in a net financing buy-in of 2.18 million yuan [1]. - As of September 25, the total financing and securities lending balance for Anxu Bio was 93.62 million yuan, which is 1.93% of its market capitalization and below the 50th percentile level over the past year, indicating a low financing balance [1]. Group 2: Securities Lending Activity - On September 25, Anxu Bio had no shares repaid or sold in securities lending, resulting in a sell amount of 0.00 yuan and a securities lending balance of 0.00 yuan, which is at a high level exceeding the 90th percentile over the past year [1]. Group 3: Financial Performance - For the first half of 2025, Anxu Bio reported a revenue of 230 million yuan, a year-on-year decrease of 7.42%, and a net profit attributable to shareholders of 59.31 million yuan, down 48.57% year-on-year [2]. - Since its A-share listing, Anxu Bio has distributed a total of 895 million yuan in dividends, with 657 million yuan distributed over the past three years [2]. Group 4: Shareholder Information - As of June 30, 2025, Anxu Bio had 6,024 shareholders, an increase of 1.50% from the previous period, with an average of 21,096 circulating shares per person, a decrease of 1.48% [2]. - Among the top ten circulating shareholders, Guangfa Value Core Mixed A held 3.01 million shares, unchanged from the previous period, while Zhaoshang Prosperity Preferred Stock A reduced its holdings by 10,000 shares to 600,000 shares [2].